Do the unintended actions of botulinum toxin at distant sites have clinical implications?

Neurology

Volumn 72, Issue 12, 2009, Pages 1095-1099

  Currà, Antonio ^a,b   Berardelli, Alfredo ^b,c,d  

^a A Fiorini Hospital   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c IRCCS NEUROMED   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; PROTEINASE; TETANUS TOXIN; TETRAZOLIUM BLUE;

BLEPHAROSPASM; CERVICAL DYSTONIA; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TRANSPORT; DRUG UPTAKE; DYSTONIA; HUMAN; MOTOR DYSFUNCTION; MUSCLE DISEASE; MYALGIA; NONHUMAN; OVERACTIVE SMOOTH MUSCLE DISORDER; PRIORITY JOURNAL; REVIEW; SPASTICITY; TRANSCYTOSIS;

EID: 67650375991     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000345010.98495.fc     Document Type: Review

References (51)

1. Naumann M, So Y, Argoff CE, et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70: 1707-1714.
2. Simpson DM, Blitzer A, Brashear A, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70: 1699-1706.
3. Simpson DM, Gracies JM, Graham HK, et al. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1691-1698.
4. Schiavo G, Rossetto O, Benfenati F, Poulain B, Montecucco C. Tetanus and botulinum neurotoxins are zinc proteases specific for components of the neuroexocytosis apparatus. Ann NY Acad Sci 1994;710:65-75.
5. Hamjian JA, Walker FO. Serial neurophysiological studies of intramuscular botulinum-A toxin in humans. Muscle Nerve 1994;17:1385-1392.
6. Lange DJ, Rubin M, Greene PE, et al. Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve 1991;14:672-675.
7. Polley EH, Vick JA, Ciuchta HP, Fischetti DA, Macchitelli FJ, Montanarelli N. Botulinum toxin, type A: effects on central nervous system. Science 1965;147: 1036-1037.
8. Simpson LI. Effects of intraperitoneally injected botulinum toxin on rat cerebral cortex levels of acetylcholine. J Neurochem 1968;15:359-360.
9. Habermann E, Erdmann G. Pharmacokinetic and histoautoradiographic evidence for the intraaxonal movement of toxin in the pathogenesis of tetanus. Toxicon 1978;16: 611-623.
10. Bigalke H, Heller I, Bizzini B, Habermann E. Tetanus toxin and botulinum A toxin inhibit release and uptake of various transmitters, as studied with particulate preparations from rat brain and spinal cord. Arch Pharmacol 1981;316:244-251.
11. Montecucco C, Schiavo G. Mechanism of action of tetanus and botulinum neurotoxins. Mol Microbiol 1994;13: 1-8.
12. Wiegand H, Erdmann G, Wellhoner HH. 125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Arch Pharmacol 1976;292:161-165.
13. Habermann E. 125I-labeled neurotoxin from Clostridium botulinum A: preparation, binding to synaptosomes and ascent to the spinal cord. Arch Pharmacol 1974;281:47-56.
14. Curra A, Trompetto C, Abbruzzese G, Berardelli A. Central effects of botulinum toxin type A: evidence and supposition. Mov Disord 2004;19 suppl 8:S60-S64.
15. Giladi N. The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J Neurol Sci 1997;152:132-135.
16. Abbruzzese G, Berardelli A. Neurophysiological effects of botulinum toxin type A. Neurotox Res 2006;9:109-114.
17. Bozzi Y, Costantin L, Antonucci F, Caleo M. Action of botulinum neurotoxins in the central nervous system: antiepileptic effects. Neurotox Res 2006;9:197-203.
18. Boroff DA, Chen GS. On the question of permeability of the blood-brain barrier to botulinum toxin. Int Arch Allergy Appl Immunol 1975;48:495-504.
19. Hirokawa N, Kitamura M. Binding of Clostridium botulinum neurotoxin to the presynaptic membrane in the central nervous system. J Cell Biol 1979;81:43-49.
20. Moreno-Lopez B, Pastor AM, de la Cruz RR, Delgado- Garcia JM. Dose-dependent, central effects of botulinum neurotoxin type A: a pilot study in the alert behaving cat. Neurology 1997;48:456-464.
21. Delaney AJ, Crane JW, Sah P. Noradrenaline modulates transmission at a central synapse by a presynaptic mechanism. Neuron 2007;56:880-892.
22. Wohlfarth K, Schubert M, Rothe B, Elek J, Dengler R. Remote F-wave changes after local botulinum toxin application. Clin Neurophysiol 2001;112:636-640.
23. Priori A, Berardelli A, Mercuri B, Manfredi M. Physiological effects produced by botulinum toxin treatment of upper limb dystonia. Changes in reciprocal inhibition between forearm muscles. Brain 1995;118:801-807.
24. Grandas F, Traba A, Alonso F, Esteban A. Blink reflex recovery cycle in patients with blepharospasm unilaterally treated with botulinum toxin. Clin Neuropharmacol 1998;21:307-311.
25. Gilio F, Curra A, Lorenzano C, Modugno N, Manfredi M, Berardelli A. Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia. Ann Neurol 2000;48:20-26.
26. Thickbroom GW, Byrnes ML, Stell R, Mastaglia FL. Reversible reorganisation of the motor cortical representation of the hand in cervical dystonia. Mov Disord 2003;18: 395-402.
27. Walsh R, Hutchinson M. Molding the sensory cortex: spatial acuity improves after botulinum toxin treatment for cervical dystonia. Mov Disord 2007;22:2443-2446.
28. Trompetto C, Curra A, Buccolieri A, Suppa A, Abbruzzese G, Berardelli A. Botulinum toxin changes intrafusal feedback in dystonia: a study with the tonic vibration reflex. Mov Disord 2006;21:777-782.
29. Kanovsky P, Streitova H, Dufek J, Znojil V, Daniel P, Rektor I. Change in lateralization of the P22/N30 cortical component of median nerve somatosensory evoked potentials in patients with cervical dystonia after successful treatment with botulinum toxin A. Mov Disord 1998;13:108-117.
30. Jankovic J. Botulinum toxin therapy for cervical dystonia. Neurotox Res 2006;9:145-148.
31. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008;64:274-283.
32. Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci 2008;28:3689-3696.
33. Caleo M, Restani L, Gianfranceschi L, et al. Transient synaptic silencing of developing striate cortex has persistent effects on visual function and plasticity. J Neurosci 2007; 27:4530-4540.
34. Folkins JW, Larson CR. In search of a tonic vibration reflex in the human lip. Brain Res 1978;151:409-412.
35. Barlow SM, Abbs JH. Orofacial fine motor control impairments in congenital spasticity: evidence against hypertonus-related performance deficits. Neurology 1984;34:145-150.
36. McComas AJ. Oro-facial muscles: internal structure, function and ageing. Gerodontology 1998;15:3-14.
37. Vaughan CW, Neilson PD, O'Dwyer NJ. Motor control deficits of orofacial muscles in cerebral palsy. J Neurol Neurosurg Psychiatry 1988;51:534-539.
38. Franchi G, Veronesi C. Short-term reorganization of input-deprived motor vibrissae representation following motor disconnection in adult rats. J Physiol 2006;574: 457-476.
39. Yildiz S, Bademkiran F, Yildiz N, Aydogdu I, Uludag B, Ertekin C. Facial motor cortex plasticity in patients with unilateral peripheral facial paralysis. Neurorehabilitation 2007;22:133-140.
40. Pastor AM, Moreno-Lopez B, De La Cruz RR, Delgado- Garcia JM. Effects of botulinum neurotoxin type A on abducens motoneurons in the cat: ultrastructural and synaptic alterations. Neuroscience 1997;81:457-478.
41. Delgado-Garcia JM, Del Pozo F, Spencer RF, Baker R. Behavior of neurons in the abducens nucleus of the alert cat: III: axotomized motoneurons. Neuroscience 1988;24: 143-160.
42. Girlanda P, Quartarone A, Sinicropi S, Nicolosi C, Messina C. Unilateral injection of botulinum toxin in blepharospasm: single fiber electromyography and blink reflex study. Mov Disord 1996;11:27-31.
43. Valls-Sole J, Tolosa ES, Marti MJ, Allam N. Treatment with botulinum toxin injections does not change brainstem interneuronal excitability in patients with cervical dystonia. Clin Neuropharmacol 1994;17:229-235.
44. Valls-Sole J, Tolosa ES, Ribera G. Neurophysiological observations on the effects of botulinum toxin treatment in patients with dystonic blepharospasm. J Neurol Neurosurg Psychiatry 1991;54:310-313.
45. Diamond ME, von Heimendahl M, Knutsen PM, Kleinfeld D, Ahissar E. 'Where' and 'what' in the whisker sensorimotor system. Nat Rev Neurosci 2008;9:601-612.
46. Berg RW, Kleinfeld D. Vibrissa movement elicited by rhythmic electrical microstimulation to motor cortex in the aroused rat mimics exploratory whisking. J Neurophysiol 2003;90:2950-2963.
47. Ahrens KF, Kleinfeld D. Current flow in vibrissa motor cortex can phase-lock with exploratory rhythmic whisking in rat. J Neurophysiol 2004;92:1700-1707.
48. Gao P, Bermejo R, Zeigler HP. Whisker deafferentation and rodent whisking patterns: behavioral evidence for a central pattern generator. J Neurosci 2001;21:5374-5380.
49. Gao P, Hattox AM, Jones LM, Keller A, Zeigler HP. Whisker motor cortex ablation and whisker movement patterns. Somatosens Mot Res 2003;20:191-198.
50. Hattox AM, Priest CA, Keller A. Functional circuitry involved in the regulation of whisker movements. J Comp Neurol 2002;442:266-276.
51. Hattox A, Li Y, Keller A. Serotonin regulates rhythmic whisking. Neuron 2003;39:343-352.